Plain-English translation of NCT05296356 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a small research study testing a medication called in people with bipolar disorder who are currently in a depressed phase. The study will follow you for 8 weeks to see how well the medication works and whether it's safe, while you continue taking your regular mood-stabilizing medication.
Bipolar depression can be difficult to treat, and people often struggle even when taking standard mood stabilizers. This study is exploring whether this new treatment might help reduce depressive symptoms in people with bipolar disorder.
You likely qualify if…
You likely don't qualify if…
You would take the new medication by mouth at a flexible dose (adjusted to what works best for you) while continuing your regular mood stabilizer. You would visit the clinic 9 times over 8 weeks plus 1 additional safety visit, where the doctors will check how you're doing, ask about any side effects, and possibly do blood tests or heart monitoring. The study is being conducted at a single center in Sweden.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Sweden
Phase
Testing effectiveness
Sponsor
Göteborg University
Collaborators
Arvid Carlsson Research AB
Enrollment target
~22 participants
Started
October 2021
Primary completion
May 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Elias Eriksson, Professor
Göteborg University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.